Literature DB >> 23983836

Neuroleptic malignant syndrome: a review for neurohospitalists.

Brian D Berman1.   

Abstract

Neuroleptic malignant syndrome (NMS) is a life-threatening idiosyncratic reaction to antipsychotic drugs characterized by fever, altered mental status, muscle rigidity, and autonomic dysfunction. It has been associated with virtually all neuroleptics, including newer atypical antipsychotics, as well as a variety of other medications that affect central dopaminergic neurotransmission. Although uncommon, NMS remains a critical consideration in the differential diagnosis of patients presenting with fever and mental status changes because it requires prompt recognition to prevent significant morbidity and death. Treatment includes immediately stopping the offending agent and implementing supportive measures, as well as pharmacological interventions in more severe cases. Maintaining vigilant awareness of the clinical features of NMS to diagnose and treat the disorder early, however, remains the most important strategy by which physicians can keep mortality rates low and improve patient outcomes.

Entities:  

Keywords:  movement disorders; neurohospitalist; neuroleptic malignant syndrome

Year:  2011        PMID: 23983836      PMCID: PMC3726098          DOI: 10.1177/1941875210386491

Source DB:  PubMed          Journal:  Neurohospitalist        ISSN: 1941-8744


  67 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome.

Authors:  L Gregorakos; T Thomaides; S Stratouli; E Sakayanni
Journal:  Clin Auton Res       Date:  2000-08       Impact factor: 4.435

3.  Apparent neuroleptic malignant syndrome with clozapine and lithium.

Authors:  H G Pope; J O Cole; P T Choras; C E Fulwiler
Journal:  J Nerv Ment Dis       Date:  1986-08       Impact factor: 2.254

Review 4.  Serotonin syndrome.

Authors:  T G Martin
Journal:  Ann Emerg Med       Date:  1996-11       Impact factor: 5.721

5.  Tricyclics and malignant syndrome.

Authors:  M Abbar; B Carlander; D Castelnau
Journal:  Eur Psychiatry       Date:  1996       Impact factor: 5.361

Review 6.  Neuroleptic malignant syndrome.

Authors:  J L Levenson
Journal:  Am J Psychiatry       Date:  1985-10       Impact factor: 18.112

Review 7.  Mortality from neuroleptic malignant syndrome.

Authors:  A Shalev; H Hermesh; H Munitz
Journal:  J Clin Psychiatry       Date:  1989-01       Impact factor: 4.384

8.  Severe and uncommon involuntary movement disorders due to psychotropic drugs.

Authors:  S Stübner; E Rustenbeck; R Grohmann; G Wagner; R Engel; G Neundörfer; H-J Möller; H Hippius; E Rüther
Journal:  Pharmacopsychiatry       Date:  2004-03       Impact factor: 5.788

Review 9.  Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome.

Authors:  M A Granner; G F Wooten
Journal:  Semin Neurol       Date:  1991-09       Impact factor: 3.420

Review 10.  [Malignant hyperthermia and its differential diagnosis].

Authors:  K Hüttemann; T Nowe; M Köhrmann; M Anetseder; P D Schellinger
Journal:  Fortschr Neurol Psychiatr       Date:  2009-04-03       Impact factor: 0.752

View more
  39 in total

1.  Early detection of an atypical presentation of neuroleptic malignant syndrome: A case report.

Authors:  P Brittany Vickery; Lindsy Meadowcraft; Stephen B Vickery
Journal:  Ment Health Clin       Date:  2018-03-23

2.  Index of suspicion. Case 2: Fever and Irritability in a 15-year-old Boy With Autism.

Authors:  Christine Westfall; Charles J Mullett; Linda S Nield
Journal:  Pediatr Rev       Date:  2015-07

3.  Neuroleptic malignant syndrome: a concealed diagnosis with multitreatment approach.

Authors:  Ana Velosa; António Neves; J Bernardo Barahona-Corrêa; Albino J Oliveira-Maia
Journal:  BMJ Case Rep       Date:  2019-06-17

4.  Beware of Neuroleptic Malignant Syndrome in COVID-19 Pandemic.

Authors:  Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2021 Jul-Sep

5.  Prevalence and risk factors related to haloperidol use for delirium in adult intensive care patients: the multinational AID-ICU inception cohort study.

Authors:  Marie O Collet; Jesús Caballero; Romain Sonneville; Fernando A Bozza; Peter Nydahl; Anna Schandl; Hilden Wøien; Giuseppe Citerio; Mark van den Boogaard; Johanna Hästbacka; Matthias Haenggi; Kirsten Colpaert; Louise Rose; Marija Barbateskovic; Theis Lange; Aksel Jensen; Martin B Krog; Ingrid Egerod; Helle L Nibro; Jørn Wetterslev; Anders Perner
Journal:  Intensive Care Med       Date:  2018-05-16       Impact factor: 17.440

Review 6.  Drug-induced hyperthermia in critical care.

Authors:  Edward Walter; Mike Carraretto
Journal:  J Intensive Care Soc       Date:  2015-04-22

7.  Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.

Authors:  Daniel Guinart; Heidi Taipale; Jose M Rubio; Antti Tanskanen; Christoph U Correll; Jari Tiihonen; John M Kane
Journal:  Schizophr Bull       Date:  2021-10-21       Impact factor: 9.306

8.  Neuroleptic Malignant Syndrome in a Patient With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: Case Report and Review of Related Literature.

Authors:  Robert Joseph C Sarmiento; Jose Danilo B Diestro; Athena Kate D Antonio; Mario B Prado; Karen Joy B Adiao; Carissa Paz Dioquino-Maligaso
Journal:  Neurohospitalist       Date:  2021-03-19

9.  Extrapyramidal Side Effects in a Patient with Alcohol Withdrawal Symptoms: A Reflection of Quality of the Mental Health Care System.

Authors:  Mark Mohan Kaggwa; Rahel Nkola; Sarah Maria Najjuka; Felix Bongomin; Scholastic Ashaba; Mohammed A Mamun
Journal:  Risk Manag Healthc Policy       Date:  2021-07-01

Review 10.  Antipsychotic dose escalation as a trigger for neuroleptic malignant syndrome (NMS): literature review and case series report.

Authors:  Julie Langan; Daniel Martin; Polash Shajahan; Daniel J Smith
Journal:  BMC Psychiatry       Date:  2012-11-29       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.